ABBV

RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more DMARDs 1 Approval was based on the open-label Phase 1 SELECT-YOUTH study and data from adults with rheumatoid arthritis 1,2 A new oral solution of RINVOQ was approved for use in patients with pJIA 1 RINVOQ is currently approved in the European Union for 11 indications across various immune-mediated, inflammatory diseases 1 NORTH CHICAGO, Ill., Sept. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral solution) for the treatment of active polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs).

Multi-year partnership applies Iambic's AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology Companies to pursue programs with both first-in-class and best-in-class potential, combining Iambic's molecular superintelligence platform with AbbVie's therapeutic area expertise NORTH CHICAGO, Ill. and SAN DIEGO, Sept.

AbbVie's Qulipta could be racing toward another label expansion, given a recent clinical trial win. This new indication could make a meaningful impact on Qulipta's sales.

AbbVie continues to diversify its revenue streams with successful expansions in immunology and aesthetics. Bristol-Myers Squibb maintains high net margins while offering a significantly lower valuation than many industry peers.

New data from prospective real-world studies of VRAYLAR showed meaningful improvements in depressive symptoms, functioning and quality of life among adults living with major depressive disorder (MDD) and bipolar I (BP-I) depression These findings provide additional evidence that the benefits observed with VRAYLAR in clinical trials can also be achieved in routine practice, where patients often have more complex treatment needs NORTH CHICAGO, Ill., Sept. 18, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today presented new VRAYLAR® (cariprazine) data at Psych Congress 2026 in New Orleans, including results from two prospective real-world observational studies in major depressive disorder (MDD) and bipolar I disorder (BP-I).

Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank the Dividend Kings using my 9F Quality Scores, blending qualitative and quantitative factors for a robust, investment-grade assessment. ADP stands out as the best total-return candidate. It is undervalued, high-quality, and offering a strong projected dividend growth rate and Adjusted Chowder Number.

A biopharma giant, a chip maker, a delivery network, a trash hauler, and an oncology powerhouse walk into the same portfolio for one reason, and it has nothing to do with chasing the highest yield.

Plenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study's dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM) Additional presentations highlight research across the breadth of AbbVie's multiple myeloma portfolio, including ABBV-2001 (ISB 2001), a trispecific T-cell engager and surzetoclax, a BCL-2 inhibitor, and combination approaches AbbVie's IMS presence reinforces its strategy to build a differentiated multiple myeloma portfolio across complementary mechanisms designed to address disease complexity and evolving patient needs NORTH CHICAGO, Ill., Sept. 17, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland.

Two studies evaluating targeted skincare and dermabrasion approaches will be presented at the 2026 Science of Skin Summit IRVINE, Calif., Sept. 17, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combination with DiamondGlow® dermabrasion treatments in individuals taking medical weight loss (MWL) medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs).

ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving strong growth and raising its 2026 outlook.